TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: An early clinical trial in which patients with CD30-positive PTCL received brentuximab vedotin administered sequentially with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or in combination with CHP and reported CR rates of 62% and 88% and 1-year PFS of 77% and 71%, respectively [81].